Tag Archives: Bioscience

Lexaria - Nicotine - Television

Lexaria Featured on Television

Lexaria Featured on Television

KELOWNA, British Columbia, May 18, 2017 /Weed Wire/ – Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is one of five companies featured on a special BTV episode exploring burgeoning cannabis enterprises.

Lexaria - Nicotine - Television

Lexaria Extends Investor Relations Agreement

KELOWNA, British Columbia, Dec. 22, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) announces it has extended the services of Frontier Merchant Capital Group (“Frontier”) with a head office in Toronto, Canada, for a period of three months. Lexaria will pay CDN $25,000 + GST.

Lexaria - Nicotine - Television

Lexaria Files International Cannabinoid Patent Applications

KELOWNA, British Columbia, Dec. 19, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce, following the successful October 26, 2016 issuance of its U.S. Patent No. 9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof, it has filed to expand this patent internationally.

Lexaria - Nicotine - Television

Lexaria Enters Memorandum of Understanding Establishing a Joint Venture with NeutriSci International Inc.

KELOWNA, British Columbia, Nov. 22, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) and NeutrisSci International Inc. (“Neutrisci”) (TSX-V:NU, Frankfurt-1N9) are pleased to announce the signing of a Memorandum of Understanding forming a 50/50 Joint Venture.

Lexaria - Nicotine - Television

Lexaria Bioscience Announces Issuance of U.S. Patent for Cannabinoid Infused Edibles

KELOWNA, British Columbia, Oct. 26, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 9,474,725 pertaining to Lexaria’s method of improving bioavailability and taste of certain cannabinoid lipophilic active agents in food products.

Lexaria - Nicotine - Television

Lexaria Appoints New Auditors

KELOWNA, British Columbia,Oct. 6, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces it has appointed Davidson and Company, LLP, Chartered Professional Accountants, as its new independent registered public auditing firm for its fiscal year ending August 31, 2016.

Lexaria - Nicotine - Television

Lexaria Closes Final Tranche of Fully Subscribed Financing

KELOWNA, British Columbia, Aug. 31, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) announces it has closed the final tranche of the private placement equity financing announced July 5. The Company is pleased that the financing was fully subscribed.

Lexaria - Nicotine - Television

New LOI Signed to Out-License Lexaria’s Technology

KELOWNA, British Columbia, Aug. 30, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (“the Company” or “Lexaria”) has entered a new letter of intent (LOI) to license its proprietary absorption and palatability enhancing technology for cannabinoids and other bioactive substances.

Lexaria - Nicotine - Television

Lexaria Receives Notice of Allowance of First Patent by US Patent Office

KELOWNA, British Columbia, July 12, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) is very pleased to announce a watershed event in its advancement as a bioscience company: it has just received its first Notice of Allowance for one of its US patent applications from the US Patent and Trademark Office (USPTO).

Lexaria - Nicotine - Television

Lexaria Intends to Complete an Equity Financing of US$300,000

KELOWNA, British Columbia, July 5, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) reports its intention to complete a non-brokered private placement financing of 5,000,000 equity units priced at US$0.06 (approx. CDN $0.078).

Axim Biotech - MedChew Rx

AXIM Biotech Announces Launch of Clinical Trials on MedChew RX™ and Development of Pharmaceutical-Grade Cannabis Chewing Gum

SAN DIEGO, Aug. 11, 2015 /Weed Wire/ — AXIM Biotechnologies, Inc. (OTC: AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products – all derived from industrial hemp.


Top